Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Equity (Unaudited)

v3.24.3
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Retained Earnings
Accumulated Other Comprehensive Income/(Loss)
Employees
Common Stock
Executive Officer
Common Stock
Director
Common Stock
Balance, beginning of period (in shares) at Mar. 31, 2023   33,508,076              
Balance, beginning of period at Mar. 31, 2023 $ 418,988 $ 33 $ 239,860   $ 237,195 $ (58,100)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to employees, executive officers and directors (in shares)             73,345 93,826 5,718
Stock compensation expense 1,238   1,238            
Repurchase of employee stock units on vesting (1,685)   (1,685)            
Net income 10,938       10,938        
Foreign currency translation adjustment 4,457         4,457      
Other 13         13      
Balance, end of period (in shares) at Jun. 30, 2023   33,680,965              
Balance, end of period at Jun. 30, 2023 433,949 $ 33 239,413   248,133 (53,630)      
Balance, beginning of period (in shares) at Mar. 31, 2023   33,508,076              
Balance, beginning of period at Mar. 31, 2023 418,988 $ 33 239,860   237,195 (58,100)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income 25,668                
Foreign currency translation adjustment (3,388)                
Balance, end of period (in shares) at Sep. 30, 2023   33,690,712              
Balance, end of period at Sep. 30, 2023 442,306 $ 34 240,833   262,863 (61,424)      
Balance, beginning of period (in shares) at Jun. 30, 2023   33,680,965              
Balance, beginning of period at Jun. 30, 2023 433,949 $ 33 239,413   248,133 (53,630)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to employees, executive officers and directors (in shares)             2,550   7,197
Stock compensation expense 1,450   1,450            
Repurchase of employee stock units on vesting (30)   (30)            
Net income 14,730       14,730        
Foreign currency translation adjustment (7,845)         (7,845)      
Other 52 $ 1       51      
Balance, end of period (in shares) at Sep. 30, 2023   33,690,712              
Balance, end of period at Sep. 30, 2023 $ 442,306 $ 34 240,833   262,863 (61,424)      
Balance, beginning of period (in shares) at Mar. 31, 2024 33,722,225 33,722,225              
Balance, beginning of period at Mar. 31, 2024 $ 474,887 $ 34 243,555 $ (250) 288,783 (57,235)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to employees, executive officers and directors (in shares)             56,614 87,782 7,241
Stock compensation expense 1,065   1,065            
Repurchase of employee stock units on vesting (2,995)   (2,995)            
Repurchase of shares under authorized program (in shares)   (49,341)              
Repurchase of shares under authorized program (1,579)     (1,579)          
Net income 8,511       8,511        
Foreign currency translation adjustment (3,879)         (3,879)      
Other (30)   1     (31)      
Balance, end of period (in shares) at Jun. 30, 2024   33,824,521              
Balance, end of period at Jun. 30, 2024 $ 475,980 $ 34 241,626 (1,829) 297,294 (61,145)      
Balance, beginning of period (in shares) at Mar. 31, 2024 33,722,225 33,722,225              
Balance, beginning of period at Mar. 31, 2024 $ 474,887 $ 34 243,555 (250) 288,783 (57,235)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income 18,005                
Foreign currency translation adjustment $ 1,708                
Balance, end of period (in shares) at Sep. 30, 2024 33,755,279 33,755,279              
Balance, end of period at Sep. 30, 2024 $ 490,287 $ 34 243,119 (4,089) 306,788 (55,565)      
Balance, beginning of period (in shares) at Jun. 30, 2024   33,824,521              
Balance, beginning of period at Jun. 30, 2024 475,980 $ 34 241,626 (1,829) 297,294 (61,145)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to employees, executive officers and directors (in shares)             924   5,586
Stock compensation expense 1,511   1,511            
Repurchase of employee stock units on vesting (18)   (18)            
Repurchase of shares under authorized program (in shares)   (75,752)              
Repurchase of shares under authorized program (2,260)     (2,260)          
Net income 9,494       9,494        
Foreign currency translation adjustment 5,587         5,587      
Other $ (7)         (7)      
Balance, end of period (in shares) at Sep. 30, 2024 33,755,279 33,755,279              
Balance, end of period at Sep. 30, 2024 $ 490,287 $ 34 $ 243,119 $ (4,089) $ 306,788 $ (55,565)